Akcea now shooting for $200M-plus as a new lineup of biotech IPOs prep for a launch

Paula Soteropoulos, CEO, Akcea

Akcea Therapeutics is upping the ante on its IPO.

The Ionis subsidiary originally mapped out a plan to raise $100 million in its initial offering, but in an amended S-1 today the company increased its potential to $155 million, with its partners at Novartis ready to pitch in with $50 million more if Akcea achieves certain financial benchmarks with investors.

Akcea spelled out plans $AKCA to sell 9.62 million shares at $12 to $14 a share with underwriters getting an option on 1.4 million shares. At the midrange, that would leave Ionis with 73.4% of the shares.

The lion’s share of the money, $80 million, is earmarked for the completion of the Phase III volanesorsen study. Akcea CEO Paula Soteropoulos plans to set aside $30 million to complete the planned Phase II program for AKCEA-APO(a)-L Rx ; $16 million to complete the planned Phase II program for AKCEA-ANGPTL3-L Rx ; and about $24 million to complete the planned Phase II program for AKCEA-APOCIII-L.

Founded in 2015, Akcea plans to go on to market volanesorsen alone in the US and Europe, with its partners at Novartis stepping in on the next two therapies — AKCEA-APO(a)-LRx. and AKCEA-APOCIII-LRx — it plans to steer to regulators.

Several biotechs are lining up for a shot at the public market, encouraged by the recent experiences of companies like Biohaven $BHVN.

Dova Pharmaceuticals just set terms on its $65 million IPO while Aileron is aiming at a $60 million score.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,700+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->